Molecule to Market: Inside the outsourcing space

• The impact of a CEO who loves to work

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler’s Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University’s master’s in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university’s Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  50:29
• From brink of bankruptcy to boom

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Garren Hillow, Executive Coach and Author. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Garren, covering: Why not being a PhD scientist really helped him in selling science How recruiting for glory enabled him to hire the best people on the planet Buying a CRO business and getting comfortable with the risk of bankruptcy Going all in on his business, and sticking true to its core vision, enabled this David to beat the sector's Goliaths From struggling to make payroll, to the perfect storm that led to a $190m sale Garren Hilow is a biotech entrepreneur, advisor, and speaker best known for co-founding Abveris, an antibody discovery company he scaled without venture capital and ultimately sold to Twist Bioscience for $ 190 M. His journey is a masterclass in building a high-value, capital-efficient business in one of the world’s toughest industries. At Abveris, Garren focused on resourcefulness, sales mastery, and building a sellable system, not just a company, allowing him to achieve a major exit while staying true to his entrepreneurial ideals. Today, Garren works with founders and CEOs across life sciences and B2B sectors, helping them build scalable, independent businesses without sacrificing control. He’s passionate about empowering entrepreneurs to create long-term value through practical skills like sales, leadership, and strategic marketing, always with an eye on sustainable, founder-friendly growth. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!  Molecule to Market is also sponsored and funded by  ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  55:43
• The CEO addicted to challenge

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Angelo Gatto, CEO at Chanelle Pharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Angelo, covering: Why he chose to follow a big pharma divestment into the CDMO industry. The tricky transition from big pharma technical to commercial CDMO BD when he had the view of "I don't like sales people"! How commercial trust is developed through preparation, character and competences Why he couldn't resist the 'made for him' CEO role at Chanelle Pharma Making key strategic decisions to that make the business very attractive to a range of future buyers. The humanisation of animal care driving the pipeline and development of new products for small and large animals Angelo brings over 25 years of international experience in pharmaceuticals, in a career spanning animal health, human health and CDMO. He has held operations, commercial and management roles at Johnson & Johnson, AlfaSigma, Pfizer, Aenova Group, Adragos Pharma.  Since July 2024 is the CEO of Chanelle Pharma, Before joining Chanelle he also created a boutique advisory firm that has helped companies in last years to succeed in M&A deals and value creation, mostly in the CDMO space. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

  --------  

  50:10
• The COO leveraging the ‘power of we’

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Christiane Bardroff, COO of Rentschler Biopharma SE. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Christiane, covering: The importance of "knowing what you're talking about" to build confidence Being asked to build and commission an automated €800m bioprocessing plant at Teva The draw of a family-owned CDMO business servicing 170 clients worldwide, and what she loves about this ownership model The 'power of we' is doing things together as a team for the greater good of the business The power of listening to people and empowering teams that led to producing 50% more at the same site Why Rentschler Biopharma decided to exit the CGT capabilities and double down on its biologics business Christiane oversees operations across the company’s sites in Germany and the US. A results-driven executive with a strong foundation in biotechnology and chemical engineering, she brings deep expertise across biomanufacturing, automation, digitalization, and leadership. Her career includes nearly a decade at Roche, where she implemented the company’s first paperless manufacturing process. At Teva Biotech, she led the development of a €800M large-scale facility and was part of the global management team, earning Teva’s Mission and Values Award in 2021. Since joining Rentschler in 2022, Christiane has advanced rapidly through senior leadership roles and now leads all operational areas, including manufacturing, quality, engineering, regulatory, and supply chain. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  51:16
• The pharma CEO focused on US commercial growth

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre’s US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  51:08

More Science podcasts

Trending Science podcasts

About Molecule to Market: Inside the outsourcing space